First-year progress in MD Anderson’s Moon Shots Program

submitted by: mdanderson
The University of Texas MD Anderson Cancer Center in September 2012 announced its Moon Shots Program, an unprecedented effort to dramatically accelerate the pace of converting scientific discoveries into clinical advances that reduce cancer deaths. The program initially targets acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung cancer; melanoma; prostate cancer; and triple-negative breast and high-grade serious ovarian cancers....

Facts about myelodysplastic syndrome

submitted by: mdanderson
Around 15,000 people in the United States are diagnosed each year with myelodysplastic syndrome (MDS). MDS occurs when the bone marrow does not properly produce one or more of the following: red blood cells, white blood cells and/or platelets. In the past it was thought MDS was only deadly when it developed into acute myelogenous leukemia (AML), but current research shows MDS can be fatal without reaching the stage of AML. Guillermo Garcia-Manero, M.D., professor in Leukemia, explains the...

UT MD Anderson Cancer Center launches unprecedented Moon Shots Program to increase patient survival during the next decade

submitted by: mdanderson
Inspired by America’s drive a generation ago to put a man on the moon, MD Anderson’s Moon Shots Program is a highly-concentrated effort to rapidly and dramatically decrease suffering and death in several major cancers, including acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); chronic lymphocytic leukemia (CLL); lung; melanoma; prostate and two cancers linked at the molecular level: triple-negative breast and ovarian. Focused teams are building on new technology and...